期刊
LEUKEMIA & LYMPHOMA
卷 54, 期 4, 页码 843-850出版社
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2012.731599
关键词
ROR1; ROR2; antibodies; flow cytometry; hematological malignancies
资金
- Vinnova
- EUCAAD [200755]
- EU
- CLL Global Research Foundation
- Cancer and Allergy Foundation
- Swedish Research Council
- Iranian Ministry of Health and Medical Education
- Swedish Cancer Society
- Cancer Society in Stockholm
- King Gustaf Vth Jubilee Fund
- Swedish Pediatric Cancer Foundation
- Karolinska Institute Foundations
- Stockholm County Council
The receptor tyrosine kinase ROR1 has been shown to be overexpressed in chronic lymphocytic leukemia (CLL). The aim of this study was to further characterize the expression of ROR1 and the other member of the ROR family, ROR2, in other lymphoid and myeloid malignancies. Normal white blood cells and reactive lymph nodes were negative for ROR1 and ROR2. A significantly high and uniform surface expression of ROR1 was found in CLL/hairy cell leukemia (HCL) compared to mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), myelomas, acute lymphoblastic leukemia (ALL) and myeloid leukemias (p = 0.02 to <0.001). The lowest proportion of ROR1+ cells was seen in FL, whereas CLL, HCL and CML had significantly higher numbers of ROR1+ cells. Longitudinal follow-up of individual patients with CLL revealed that ROR1+ cells remained stable over time in non-progressive patients, but increased when the disease progressed (p < 0.05). Thus, a variable staining pattern of ROR1 ranging from very high (CLL, HCL) and high (CML) to intermediate (myeloma and DLBCL) or low (FL) was noted. ROR2 was not detected in hematological malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据